Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07216105 · ClinicalTrials.gov registry record · Phase 1

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Fate Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
113
Enrollment target
3
Study locations

NCT07216105 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is actively recruiting participants, run by Fate Therapeutics. The registered enrollment target is 113 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07216105, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Fate Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
113 participants
Enrollment target
3
Study locations

Study Summary

This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836 in combination with trastuzumab or cetuximab; each objective will be assessed with or without paclitaxel chemotherapy.

Conditions Studied

Breast Cancer Non-Small Cell Lung Cancer Colorectal Cancer Ovarian Cancer Head and Neck Squamous Cell Carcinoma Endometrial Carcinoma

Interventions

  • DRUG Trastuzumab
  • DRUG Paclitaxel
  • DRUG Cetuximab
  • DRUG FT836

Study Locations (3)

Minnesota

  • University of Minnesota Masonic Cancer Center - Minneapolis

Pennsylvania

  • Thomas Jefferson University, Sidney Kimmel Cancer Center - Philadelphia

Texas

  • M. D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 113 participants
Start Date 2025-11-04
Est. Completion 2030-01
Phase Phase 1

Sponsor

Fate Therapeutics

22 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07216105

The ClinicalTrials.gov registry entry for NCT07216105 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Trastuzumab is the first listed.

NCT07216105 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Minnesota, Pennsylvania, Texas.

Frequently Asked Questions

What is clinical trial NCT07216105 about?

NCT07216105 is a clinical study titled "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors". This is a phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without paclitaxel and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT836...

What is the current status of trial NCT07216105?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2025-11-04. Estimated completion is 2030-01.

What conditions does trial NCT07216105 study?

This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT07216105?

The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), Cetuximab (DRUG), FT836 (DRUG).

Who is sponsoring clinical trial NCT07216105?

This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07216105 being conducted?

This trial has 3 study locations across Minnesota, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Non-Small Cell Lung Cancer

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.